Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOAC versus antiplatelet therapy in ESUS with atrial myopathy
ACTRN12625000104459Phase 3Not yet recruiting
- Sponsor
- Hunter New England Local Health District
- Start
- Mar 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban, apixaban, dabigatran, aspirin and clopidogrel in ischemic stroke and embolic stroke of undetermined source (ESUS) (3 arms), sponsored by Hunter New England Local Health District. Primary endpoints: Stroke recurrence, Clinical recurrence of stroke and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
rivaroxabanapixabandabigatranaspirinclopidogrel
03
Conditions
ischemic strokeembolic stroke of undetermined source (ESUS)
Beyond the preview
Go deeper on ACTRN12625000104459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000104459.